摘要：目的 分析连续性肾替代治疗(CRRT)联合前列地尔对重型肝炎合并肝肾综合征患者的临床疗效及安全性。方法 选择200例我院收治的重型肝炎合并肝肾综合征患者，依据随机原则分为两组，对照组予以前列地尔治疗；治疗组予以CRRT联合前列地尔治疗。两组均为100例患者，均给予常规治疗，疗程均为3周。比较两组治疗后临床疗效、肝肾功能指标及不良反应发生率的差异。结果 与对照组相比，研究组的显效率及总有效率显著较高，而无效率则显著较低(P<0.05)。与治疗前相比，两组治疗后的各项肝肾功能指标均有所改善(P<0.05)。与对照组相比，研究组的各项肝肾功能指标均较优(P<0.05)。两组患者不良反应发生率均无统计学差异(P>0.05)。结论 CRRT联合前列地尔治疗重型肝炎合并肝肾综合征的患者临床疗效显著且安全性高。

Abstract：Objective To evaluate the clinical effect of the continuous renal replacement therapy (CRRT) and alprostail in the treatment of the late-stage severe hepatitis with hepatorenal syndrome. Methods 200 cases of patients with late-stage severe hepatitis with hepatorenal syndrome were divided into two groups randomly, which were control group (receiving the treatment of alprostail) and research group (receiving the treatment of CRRT and alprostail). Each group had 60 cases and the course of the treatment was both 3 weeks. All patients were received the common medical treatment. The indexes of clinical efficacy, hepatic and renal functions, and occurrences of adverse reaction were compared between two groups. Results Compared to control group, the indexes of total effective rate and significant efficiency rate in research group were higher (P<0.05), but the ineffective rate in research group were lower (P<0.05). Compared to control group, the indexes of hepatic and renal functions in research group were better (P<0.05). There was no significantly difference on occurrences of adverse reactions between two groups (P>0.05). Conclusion The clinical effect of CRRT and alprostail to patients with late-stage severe hepatitis with hepatorenal syndrome might be perfect and the adverse reactions are no augment.